新冠疫情时代的米勒-费雪综合征——一种新型靶抗原呼唤新型治疗方法
Miller Fisher Syndrome in the COVID-19 Era - A Novel Target Antigen Calls for Novel Treatment.
作者信息
Kajani Surina, Kajani Raheem, Huang Chin-Wei, Tran Tu, Liu Antonio K
机构信息
Medicine, Adventist Health White Memorial, Los Angeles, USA.
Critical Care, Los Angeles Community Hospital, Los Angeles, USA.
出版信息
Cureus. 2021 Jan 1;13(1):e12424. doi: 10.7759/cureus.12424.
Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument, lack of GQ1b serves as the indirect proof that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is probably the infection preceding demyelination. A novel antigen has yet to be described.
尽管在2019冠状病毒病（COVID-19）大流行期间已有米勒-费希尔综合征病例的报道，但迄今为止尚未发现抗GQ1b抗体。由于确切的病理生理学尚不清楚，因此尚未有直接的关联证据。通过反证法，缺乏GQ1b可作为间接证据，表明严重急性呼吸综合征冠状病毒2（SARS-CoV-2）可能是脱髓鞘之前的感染源。一种新的抗原尚未被描述。
Zotero 插件